Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site

Blood

Volumn 105, Issue 11, 2005, Pages 4362-4368

  Nogami, Keiji ^a   Zhou, Qian ^a   Wakabayashi, Hironao ^a   Fay, Philip J ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 10A; HISTIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; SERINE; THROMBIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD CLOTTING; CATALYSIS; COMPLEX FORMATION; DISEASE SEVERITY; HEMOPHILIA A; MICHAELIS CONSTANT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; WILD TYPE;

EID: 19344376366     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3939     Document Type: Article

References (39)

1. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.
3. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
4. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta. 1986;871:268-278.
5. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood. 1989;74:1021-1024.
6. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512.
7. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 2004;18:1-15.
8. Fay PJ, Mastri M, Koszelak ME, Wakabayashi H. Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa. J Biol Chem. 2001;276:12434-12439.
9. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10451-10455.
10. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995;270:8546-8552.
11. Donath MS, Lenting PJ, van Mourik JA, Mertens K. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J Biol Chem. 1995;270:3648-3655.
12. Lazarchick J, Hoyer LW. Immunoradiometric measurement of factor VIII procoagulant antigen. J Clin Invest. 1978;62:1048-1052.
13. Peake IR, Bloom AL, Giddings JC, Ludlum CA. An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia A. Br J Haematol. 1979;42:269-281.
14. Hoyer LW, Breckenridge RT. Immunologic studies of antihemophilic factor: crossreacting material in a genetic variant of hemophilia A. Blood. 1968;32:962-971.
15. Kemball-Cook G, Tuddenham EGD, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26:216-219.
16. Arai M, Inaba H, Higuchi M, et al. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrambin cleavage site (arginine-372 to nistidine). Proc Natl Acad Sci U S A. 1989;86:4277-4281.
17. O'Brien DP, Pattinson JK, Tuddenham EGD. Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A. Blood. 1990;75:1664-1672.
18. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest. 1988;82:123-128.
19. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure: reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991;266:8957-8962.
20. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424-27431.
21. Casillas G, Simonetti C, Pavlovsky A. Artificial substrate for the assay of factor V and VIII. Coagulation. 1971;4:107-111.
22. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833-840.
23. Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood. 2002;100:501-508.
24. Wakabayashi H, Freas J, Zhou Q, Fay PJ, Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. J Biol Chem. 2004;279:12677-12684.
25. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol. 1993;222:128-143.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
27. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem. 1996;271:6027-6032.
28. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A. 1988;85:2429-2433.
29. Shima M, Ware J, Yoshioka A, Fukui H, Fulcher CA. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood. 1989;74:1612-1617.
30. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem. 1990;265:17854-17858.
31. Johnson DJ, Pemberton S, Acquila M, Mori PG, Tuddenham EG, O'Brien DP. Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A. Thromb Haemostasis. 1994;71:428-433.
32. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem. 1991;266:12481-12486.
33. Hoyer LW, Trabold NC. The effect of thrombin on human factor VIII: cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med. 1981;97:50-64.
34. Higgins DL, Shafer J. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα16 by a histidyl residue. J Biol Chem. 1981;256:12013-12017.
35. Lane DA, Southan C, Ireland H, Thompson E, Kehl M, Menschen A. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide. Br J Haematol. 1983;53:587-597.
36. Southan C, Lane DA, Bode W, Henschen A. Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aα Arg-16 to his substitution. Eur J Biochem. 1985;147:593-600.
37. Martin PD, Robertson W, Turl D, Huber R, Bode W, Edwards BFP. The structure of residues 7-16 of the Aα-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem. 1992;267:7911-7920.
38. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem. 1996;271:13882-13887.
39. Myles T, Yun TH, Leung LL. Structural requirements for the activation of human factor VIII by thrombin. Blood. 2002;100:2820-2826.